Novartis AG (NYSE:NVS) has earned an average rating of “Hold” from the fourteen brokerages that are presently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and one has given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $85.39.
NVS has been the topic of several recent analyst reports. Nord/LB reaffirmed a “neutral” rating on shares of Novartis in a research report on Tuesday, January 2nd. Bank of America lowered Novartis from a “neutral” rating to an “underperform” rating in a report on Wednesday, December 6th. Zacks Investment Research lowered Novartis from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. UBS Group restated a “neutral” rating on shares of Novartis in a research note on Monday, January 15th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novartis in a research report on Thursday, January 18th.
Novartis (NVS) traded up $0.40 during trading hours on Friday, hitting $82.76. The stock had a trading volume of 2,390,000 shares, compared to its average volume of 1,850,000. Novartis has a fifty-two week low of $72.67 and a fifty-two week high of $94.19. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.21 and a quick ratio of 0.91. The company has a market cap of $215,620.00, a PE ratio of 25.23, a PEG ratio of 1.92 and a beta of 0.78.
Several hedge funds have recently bought and sold shares of NVS. Wealthcare Advisory Partners LLC purchased a new stake in shares of Novartis during the third quarter valued at approximately $106,000. Pinnacle Wealth Planning Services Inc. purchased a new position in shares of Novartis in the fourth quarter valued at $113,000. Calton & Associates Inc. purchased a new position in shares of Novartis in the fourth quarter valued at $118,000. SeaCrest Wealth Management LLC purchased a new position in shares of Novartis in the fourth quarter valued at $124,000. Finally, Trustcore Financial Services LLC purchased a new position in shares of Novartis in the fourth quarter valued at $178,000. Institutional investors own 10.80% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Novartis AG (NVS) Given Consensus Recommendation of “Hold” by Analysts” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://sportsperspectives.com/2018/03/11/novartis-ag-nvs-given-consensus-recommendation-of-hold-by-analysts.html.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.